NCT05905341View on ClinicalTrials.gov

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

January 15, 2024

Primary Completion Date

April 14, 2026

Study Completion Date

April 13, 2028

Conditions

Breast CancerOvarian CancerLiposarcomaNon-small Cell Lung Cancer (NSCLC)EndometrialSolid Tumors

Interventions

DRUG

PF-07224826

Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.

COMBINATION_PRODUCT

Fulvestrant

Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).

DRUG

PF-07224826

Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.

COMBINATION_PRODUCT

Fulvestrant

Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).

DRUG

PF-07224826

Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.

COMBINATION_PRODUCT

Fulvestrant

Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).

DRUG

PF-07224826

Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.

COMBINATION_PRODUCT

Fulvestrant

Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).

DRUG

PF-07224826

Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.

COMBINATION_PRODUCT

Fulvestrant

Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).

DRUG

PF-07224826

Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.

COMBINATION_PRODUCT

Fulvestrant

Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).

DRUG

PF-07224826

Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.

COMBINATION_PRODUCT

Fulvestrant

Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY

NCT05905341 - Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors. | Biotech Hunter | Biotech Hunter